Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Announces Positive Phase 1 Data for TERN-701
Summary
Terns Pharmaceuticals, Inc. announced findings from its ongoing Phase 1 study of TERN-701, an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML). The study, conducted in healthy volunteers, showed that TERN-701 can be dosed once-daily without regard to food, potentially offering a more convenient treatment option compared to existing therapies. The company plans to present these data at an upcoming scientific conference and anticipates reporting interim data from a Phase 1 trial in CML patients in the second half of 2024.
Profitelligence Alerts
Get alerts for TERN
Be first to know when Terns Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic candidates targeting liver disease and oncology. Its primary function is to advance its pipeline of clinical and preclinical drug candidates that address significant unmet medical needs. One of the company's main focuses is on non-alcoholic steatohepatitis (NASH), a progressive liver disease. Through innovative approaches, Terns Pharmaceuticals explores various mechanisms to treat NASH, including small molecules designed to reduce liver inflammation and fibrosis. Beyond liver disease, the company is expanding its platform to include oncology, diversifying its impact in the healthcare industry. As a key player in the biopharmaceutical sector, Terns Pharmaceuticals Inc. contributes to the growing landscape of targeted therapies. With a dedicated emphasis on research and development, the company plays an essential role in pushing the boundaries of treatment options, potentially transforming the management of chronic liver diseases and cancer.
Official SEC Documents
Advertisement